GSK must pay AstraZeneca royalties on Zejula, UK court rules
GSK must pay royalties to AstraZeneca on total sales of its ovarian cancer drug Zejula, a UK court ruled on Wednesday.
The case traces back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
